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a b s t r a c t
This systematic review with meta-analysis sought to determine the efﬁcacy and safety of
unfractionated heparin (UFH) and low molecular weight heparin (LMWH) on clinical out-
comes following percutaneous coronary intervention. Medline, Embase, Elsevier, and web of
knowledge as well as Google scholar literature were used for selecting appropriate studies
with randomized controlled design. After screening 445 studies, a total of 23 trials (including
a total of 43,912 patients) were identiﬁed that reported outcomes. Pooled analysis revealed
that LMWH compared to UFH could signiﬁcantly increase thrombolysis in myocardial
infarction grade 3 ﬂow (p < 0.001), which was associated with similar target vessel revascu-
larization (p = 0.6), similar incidence of stroke (p = 0.7), and signiﬁcantly lower incidence of
re-myocardial infarction (p < 0.001), major bleeding (p = 0.02) and mortality (p < 0.001). Overall,
LMWH was shown to be a useful type of heparin for patients with MI undergoing PCI, due to
its higher efﬁcacy and lower rate of complication compared to UFH. It is also associated
with increased myocardial perfusion, decreased major hemorrhage, and mortality.
# 2016 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.
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Ischemic heart disease is the leading cause of morbidity and
mortality worldwide, whereas it is expected to signiﬁcantly
increase the disease burden over the next 10 years.1 Ischemia-
reperfusion injury (IRI) is a well-known phenomenon in* Corresponding author.
E-mail address: S.alihassan.cardiosurg@gmail.com (S. Ali-Hassan-S
http://dx.doi.org/10.1016/j.ihj.2016.01.014
0019-4832/# 2016 Cardiological Society of India. Published by Elsevierthrombolysis, percutaneous coronary intervention, coronary
artery bypass grafting, and cardiac transplantation. IRI is
clinically manifested as a damage of myocardial cells due to
myocardial stunning, microvascular injury, and myocyte
necrosis.2 In patients with ST-segment elevation myocardial
infarction (STEMI) or acute coronary syndrome without ST
elevation (non-STEMI or unstable angina), early mechanicalayegh).
 B.V. All rights reserved.
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 2 1 3 – 2 2 4214or pharmacological reperfusion, anti-thrombotic therapy
with aspirin, thienopyridine, glycoprotein IIb/IIIa inhibitors,
and unfractionated heparin (UFH) have become the standard
of care and have been widely used for decreasing mortality
and myocardial infarction (MI).3,4 However, due to its
structural defects, the utilization of UFH has many limita-
tions, such as short half-life, low bioavailability, and non-
speciﬁc binding to proteins that lead to variability of
dose-anticoagulant effects.5,6 On the other hand, UFH may
activate platelets just a few minutes after administration and
may lead to thrombocytopenia.5,6 UFH has unpredictable
pharmacokinetics; thus there is a need to monitor activated
clotting time for adjusting the dose of UFH.7–9 Low molecular
weight heparin (LMWH) is an alternative anticoagulant charac-
terized by more predictable and stable anti-coagulation without
the need for continuous infusion or tight monitoring of
activated clotting time.7–9 Furthermore, it demonstrates less
protein binding, less platelet activation and relatively greater
inhibition of the coagulation cascade compared to UFH, as it has
a ratio of 4.3:1 in its anti-factor Xa to anti-factor IIb activity.10
Several previous reports indicated that LMWH was shown to be
non-inferior to UFH in terms of reducing the risk of morbidity
and mortality at 30 days.11–14This systematic review with meta-
analysis sought to determine the strength of evidence for
evaluating the efﬁcacy and safety of UFH and LMWH in patients
with MI undergoing PCI.
2. Methods and materials
2.1. Literature search
A comprehensive literature search was conducted in major
electronic databases (Medline/Pubmed, Embase, Elsevier, Web
of Knowledge and Google Scholar) from their inception through
July 20, 2014 to identify randomized controlled trials (RCTs)
reporting on the use of UFH vs. LMWH including clinical
outcomes in patients with MI undergoing percutaneous coro-
nary intervention. Predeﬁned search terms included: ‘‘unfrac-
tionated heparin’’, ‘‘UFH’’, ‘‘low molecular weight heparin’’,
‘‘LMWH’’, ‘‘enoxaparin’’, and ‘‘myocardial infarction’’, ‘‘MI’’,
‘‘ST-segment myocardial infarction’’, ‘‘STEMI’’, ‘‘acute coronary
syndrome’’, ‘‘non-STEMI’’, and ‘‘percutaneous coronary inter-
vention’’, ‘‘PCI’’, and ‘‘angioplasty’’. No language restrictions
were applied. All retrieved references of the included RCT were
also reviewed to determine additional studies not indexed in
common databases. Studies were included into the analysis
when they met the following criteria: (1) RCT, (2) reporting at
least one of the outcomes of interest including: thrombolysis in
myocardial infarction (TIMI) score, re-MI, stroke, thrombosis,
major bleeding, target vessel revascularization (TVR), major
adverse cardiovascular events (MACE), and mortality. Abstracts
and manuscripts that did not undergo peer-review, duplicate
reports and ongoing RCTs were not included.
2.2. Data extraction and outcome measures
Two investigators (S.A.-H.-S. and A.S.) extracted data indepen-
dently, and discrepancies were resolved via a consensus
standardized abstraction check-list used for recording data ineach study. Data retrieved from trials included: author's name,
country study design, details of therapeutic regimens, clinical
scenario, sample size, follow-up duration, mean age and gender,
and clinical outcomes of interest. For exploration of heteroge-
neity among the trials, a subgroup analysis of disparities
in the patients' characteristics was performed for1: follow-up
(≤6 months vs. >6 months),2 clinical scenario of patients (STEMI
vs. ACS and non-STEMI),3 type of administration (intravenous
vs. subcutaneous),4 and sample size (≤500 vs. >500).
2.3. Deﬁnitions of endpoints
TVR was deﬁned as ischemia-driven revascularization of the
infarct-related artery with PCI and coronary artery bypass
graft. Re-infarction was deﬁned as recurrent symptoms
suggestive of ischemia with ST-segment elevation and/or
elevation of the levels of cardiac markers. TIMI 0 ﬂow (no
perfusion) refers to the absence of any antegrade ﬂow beyond
the occlusion; TIMI 1 ﬂow (penetration without perfusion) is a
faint antegrade ﬂow beyond the occlusion, with incomplete
ﬁlling of the distal coronary bed; TIMI 2 ﬂow (partial perfusion)
is a delayed or sluggish antegrade ﬂow with complete ﬁlling of
the distal territory; TIMI 3 ﬂow (complete perfusion) is a
normal ﬂow, which ﬁlls the distal coronary bed completely.
Mortality was considered cardiac, unless a non-cardiac cause
of death could be established. MACE were deﬁned as
composition of death or MI or major cerebrovascular event.
2.4. Statistical analysis, publication bias and quality
assessment
Data were analyzed by using STATA version 11.0 utilizing
METAN and METABIAS modules. The effect sizes measured
were odds ratio (OR) with 95% conﬁdence interval (CI) for
categorical variables. OR <1 favored LMWH and OR >1 favored
UFH group. RCTs with no events in the two arms were
discarded from pooled analysis. Forest plots were created for
each outcome. Values of p < 0.1 for Q test or I2 > 50% indicated
signiﬁcant heterogeneity among studies. Heterogeneity
among the trials was accounted for by applying a random
effect model when indicated. The presence of publication bias
was evaluated using Begg and Egger tests. Quality assessment
of RCTs was performed using the Jadad score. The Jadad
score assesses 3 items including randomization (0–2 points),
blinding of study (0–2 points) and withdrawals and dropouts
(0–1 points). Higher scores indicate better reporting (‘‘high’’
quality: 5; ‘‘good’’ quality: 3–4; ‘‘poor’’ quality: 0–2). Results
were considered statistically signiﬁcant at a p-value <0.05.
3. Results
3.1. Literature search strategy and included trials
Our literature search retrieved a total of 445 studies from
screened databases of which 295 (66.2%) were excluded after
initial review (Fig. 1). Of 150 primary included studies, 127 were
excluded after detailed evaluation due to insufﬁcient infor-
mation on endpoints of interest. Thus, the ﬁnal analysis
included 23 RCTs.
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Fig. 1 – Forest plot of odds ratio (OR) for treatment with heparin on incidence of thrombolysis in myocardial infarction score 3
flow.
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clinical outcomes
4.1. Thrombolysis in myocardial infarction grade 3
(TIMI-3)
A total of 14,276 patients were included from 6 RCTs reporting
data on TIMI score (Table 1). Patient's populations of the RCTs
ranged from 60 to 4676 patients. In this meta-analysis, 6890
patients were allocated to LMWH and 7385 to the UFH group.
The overall incidence of TIMI-3 was 60.55% ranging from 9.89%
to 97.49% (Table 2). Pooled treatment effect analysis revealed
that LMWH compared to UFH therapy signiﬁcantly increased
TIMI-3 ﬂow with an OR of 1.17 (95% CI: 1.074–1.284; p < 0.001)
using the random effects model (Fig. 1). Signiﬁcant heteroge-
neity was observed among the RCTs (chi-squared = 22.72,
I2 = 78%, p < 0.001). A subgroup analysis is presented in Table 3.
Pooled treatment effect analysis revealed that LMWH com-
pared to UFH therapy signiﬁcantly increased TIMI-3 ﬂow in
patients with STEMI (OR of 1.18; 95% CI: 1.07–1.29; p = 0.001)
compared to ACS and non-STEMI patients (OR of 0.99; 95% CI:
0.60–1.68; p = 0.9), as well as intravenous administration (OR of
1.48; 95% CI: 1.29–1.71; p = 0.001) compared to subcutaneous
administration (OR of 0.90; 95% CI: 0.70–1.14; p = 0.3). Begg and
Egger tests showed that there were no potential publication
bias among the included RCTs (Begg test, p = 0.188; Egger test,
p = 0.188).4.2. TVR
A total of 9961 patients were included from 7 RCTs reporting
data on the incidence of TVR. Patient's populations of RCTs
ranged from 83 to 3528 patients (Table 1). 5335 patients were
allocated to LMWH, whereas 4626 to the UFH group. The
overall incidence of TVR was 1.29% ranging from 0.38% to
6.02%. TVR occurred in 1.18% in LWMH group and 1.41% in UFH
group (Table 2). Pooled analysis revealed that the incidence of
TVR was similar between patients receiving LMWH or UFH
with an OR of 0.916 (95% CI: 0.641–1.309; p = 0.6) using the ﬁxed
effects model (Fig. 2). No signiﬁcant heterogeneity was
observed among the RCTs (chi-squared = 7.62, I2 = 34.4%,
p = 0.17). Begg and Egger tests showed that there were no
potential publication bias among the included RCTs (Begg test,
p = 0.453; Egger test, p = 0.453).
4.3. Incidence of stroke
A total of 22,688 cases were included from 8 RCTs reporting
data on the incidence of stroke. After removing an RCTs with
no events in 2 arms, a total of 22,488 patients were included in
the meta-analysis from 7 remaining studies (Table 1). Patient's
population of RCTs ranged from 83 to 6299 patients. In this
analysis 7909 patients were allocated to LMWH and 14,579 to
the UFH group. The overall incidence of stroke was 0.86%
ranging from 0.4% to 2.4%. Stroke occurred in 0.82% in LMWH
group and 0.88% in UFH group (Table 2). Pooled analysis
Table 1 – Demographic data of included studies.
Follow-up Study
population
Route of
administration
Male (%) Mean age
(years)
n Year/country Author
(references)
UFH LMWH UFH LMWH UFH LMWH
In-hospital STEMI N.D. 70.4 66.3 65.7 67.9 5690 609 2008/Germany Zaymer15
In-hospital ACS N.D. 62.3 58.2 71.9 72.4 3628 1178 2006/Germany Zeymer16
1 month ACS Intravenous 69.3 68 67 67 2364 2323 2006/Germany SYNERGY Trial17
4 years STEMI Intravenous 73.3 76.6 61.2 60.5 60 60 2011/China Li18
1 month STEMI Intravenous 81.4 80.5 58 58 1431 1429 2005/USA CLARITY-TIMI 2819
1 month Angina
pectoris
Intravenous 73 83 60 61 30 30 1999/USA Rabah20
1 month Non-STEMI Intravenous 73.9 75.4 63.5 63.4 1230 2298 2006/France STEEPLE trial21
3 years STEMI and
ACS
N.D. 66.3 69.4 68.9 65.5 922 1932 2012/France FAST-MI22
1 month STEMI Intravenous 78 78.4 60 59 460 450 2011/France
and Germany
ATOLL trial23
1 month STEMI Combined 74.1 73.1 63 63 1693 759 2010/USA FINESSE trial24
1 month Non-STEMI Intravenous 72 77 64 59 100 100 2005/Canada ACTION trial25
8 months STEMI Subcutaneous 75.1 73.2 62.6 62.2 1841 1531 2010/Korea Li26
8 months Non-STEMI Subcutaneous 69.4 67.4 63.7 63.7 1219 1178 2012/Korea Li27
1 month STEMI Subcutaneous 82.5 82.3 55 56 448 498 2012/Canada TRANSFER-AMI
trial28
1.2 years STEMI Combined 63.6 66.6 65 58 44 39 2008/USA Khoobiar29
1 month ACS Intravenous 63.3 67.6 64.4 61.2 71 68 2006/Korea Her30
1 month STEMI Combined 82.7 82.1 57 57 2404 2272 2007/Germany Ex-TRACT-TIMI
trial31
In-hospital STEMI Intravenous 69.3 74 61 62 49 50 2002/Spain Galeote32
1 month STEMI and
ACS
N.D. 75 77 59 60 624 590 2003/Belgium ASSENT-3-PCI
trial33
In-hospital STEMI and
ACS
Intravenous 56.8 54.9 54 54.6 271 222 2009/USA Diez34
1 month STEMI Intravenous 81.2 75.7 63.8 61.9 234 346 2010/Australia Brieger35
1 month STEMI and
ACS
Intravenous 75.8 76.7 63.7 63.3 132 129 2003/USA CRUISE trial36
1 month ACS Intravenous N.D. N.D. N.D. N.D. 440 436 2010/Switzerland Zeus37
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 2 1 3 – 2 2 4216revealed that the incidence of stroke was similar between
LMWH and UFH groups with an OR of 0.941 (95% CI: 0.680–
1.302; p = 0.7) using the ﬁxed effects model (Fig. 3). No
signiﬁcant heterogeneity was observed among the RCTs
(chi-squared = 8.75, I2 = 31.4%, p = 0.18). Begg and Egger tests
showed that there were no potential publication bias among
the included RCTs (Begg test, p = 1.000; Egger test, p = 1.000).
4.4. Re-myocardial infarction
A total of 40,008 patients were included from 19 RCTs
reporting data on the incidence of re-MI (Table 1). After
removing a single study with ‘‘zero columns’’ in 2 compara-
tive arms, from 39,948 remaining cases, 17,041 patients were
allocated to LMWH and 22,907 to UFH group. The overall
incidence of re-MI was 4.39% ranging from 0.29% to 12.5%. Re-
MI occurred in 3.8% in LMWH group and 4.8% in UFH group
(Table 2). Pooled analysis indicated that LMWH compared to
UFH signiﬁcantly decreased the incidence of re-MI with an OR
of 0.759 (95% CI: 0.681–0.847; p < 0.001) using the random
effects model (Fig. 4). Signiﬁcant heterogeneity was observed
among the RCTs (chi-squared = 42.62, I2 = 60.1%, p = 0.001). A
subgroup analysis is presented in Table 3. Pooled treatment
effect analysis revealed that LMWH compared to UFH therapy
signiﬁcantly decreased incidence of re-MI in patients with
STEMI (OR of 0.66; 95% CI: 0.54–0.80; p = 0.001) and ACS andnon-STEMI (OR of 0.78; 95% CI: 0.68–0.90; p = 0.001), whereas
intravenous administration (OR of 0.80; 95% CI: 0.71–0.92;
p = 0.001) was more effective than subcutaneous administration
(OR of 0.62; 95% CI: 0.37–1.02; p = 0.06). Begg and Egger tests
showed that there were no potential publication bias among
the included RCTs (Begg test, p = 0.506; Egger test, p = 0.506).
4.5. Major bleeding
A total of 43,912 patients were included from 23 RCTs reporting
data on the incidence of major bleeding (Table 1). After
removing 2 studies with ‘‘zero columns’’ in 2 comparative
arms, from remaining 43,573 cases enrolled in the analysis,
18,359 were allocated to LMWH and 25,214 to UFH group. The
overall incidence of major bleeding was 2.85% ranging from
0.29% to 8.27%. Major bleeding occurred in 2.12% in LMWH
group and 3.37% in UFH group (Table 2). Pooled analysis
indicated that LMWH compared to UFH signiﬁcantly decreased
the incidence of major bleeding with an OR of 0.856 (95% CI:
0.751–0.976; p = 0.02) using the random effects model (Fig. 5).
Signiﬁcant heterogeneity was observed among the RCTs (chi-
squared = 30.51, I2 = 34.4%, p = 0.06). A subgroup analysis is
presented in Table 3. Intravenous administration (OR of 0.72;
95% CI: 0.57–0.89; p = 0.004) was more efﬁcient than subcuta-
neous administration (OR of 0.90; 95% CI: 0.54–1.50; p = 0.6) for
decreasing the incidence of major hemorrhage. Begg and Egger
Table 2 – Clinical outcomes of included studies.
Jadad MACE Thrombosis Mortality Re-MI Major
bleeding
TVR TIMI 3 ﬂow Stroke Author (references)
UFH LMWH UFH LMWH UFH LMWH UFH LMWH UFH LMWH UFH LMWH UFH LMWH UFH LMWH
1 842 62 N.D. N.D. 569 44 302 19 313 40 N.D. N.D. N.D. N.D. 46 9 Zeymer15
1 268 46 N.D. N.D. 123 32 149 14 163 61 N.D. N.D. N.D. N.D. 36 11 Zeymer16
4 336 304 N.D. N.D. 43 39 312 274 38 35 N.D. N.D. N.D. N.D. N.D. N.D. SYNERGY Trial17
2 4 2 1 1 3 1 3 3 1 0 1 1 N.D. N.D. N.D. N.D. Li18
4 180 109 400 315 68 44 101 54 31 23 N.D. N.D. 802 952 22 18 CLARITY-TIMI 2819
3 N.D. N.D. 0 0 0 0 0 0 1 1 N.D. N.D. 28 29 N.D. N.D. Rabah20
3 70 138 N.D. N.D. 5 13 65 126 34 28 8 22 N.D. N.D. N.D. N.D. STEEPLE trial21
2 N.D. N.D. N.D. N.D. 85 62 12 37 32 33 N.D. N.D. N.D. N.D. 8 19 FAST-MI22
3 155 126 2 4 29 17 20 10 22 20 N.D. N.D. 46 44 1 3 ATOLL trial23
4 135 40 N.D. N.D. 95 29 N.D. N.D. 78 21 N.D. N.D. N.D. N.D. N.D. N.D. FINESSE trial24
2 14 8 N.D. N.D. 0 0 14 8 0 0 0 0 N.D. N.D. 0 0 ACTION trial25
2 213 149 N.D. N.D. 116 45 8 2 11 8 26 27 1731 1428 N.D. N.D. Li26
2 92 89 N.D. N.D. 16 20 12 3 3 4 25 10 1189 1148 N.D. N.D. Li27
3 35 36 N.D. N.D. 11 12 21 22 18 17 N.D. N.D. N.D. N.D. N.D. N.D. TRANSFER-AMI trial28
2 4 3 0 1 3 1 N.D. N.D. 2 0 3 2 N.D. N.D. 2 0 Khoobiar29
2 N.D. N.D. 0 0 0 0 2 1 0 0 N.D. N.D. N.D. N.D. N.D. N.D. Her30
5 355 261 N.D. N.D. 71 66 53 53 39 32 N.D. N.D. 632 615 14 5 Ex-TRACT-TIMI trial31
3 7 7 10 12 0 1 3 4 4 1 N.D. N.D. N.D. N.D. N.D. N.D. Galeote32
2 23 18 N.D. N.D. 17 15 13 8 16 23 N.D. N.D. N.D. N.D. N.D. N.D. ASSENT-3-PCI trial33
2 N.D. N.D. 0 0 0 0 N.D. N.D. 6 2 N.D. N.D. N.D. N.D. N.D. N.D. Diez34
2 30 25 N.D. N.D. 17 11 6 2 21 27 N.D. N.D. N.D. N.D. N.D. N.D. Brieger35
3 10 11 1 1 0 0 10 11 2 3 1 0 N.D. N.D. N.D. N.D. CRUISE trial36
2 N.D. N.D. N.D. N.D. 0 0 N.D. N.D. 17 11 N.D. N.D. N.D. N.D. N.D. N.D. Zeus37
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Table 3 – Subgroup analysis for clinical outcomes.
Subgroup Studies
(n)
Odd ratio
(95% CI)
p-Value
S.G.A. for TIMI 3 ﬂow according to OR
Sample size
>500 5 1.174 (1.073–1.28) 0.001
≤500 1 2.071 (0.17–24.14) 0.561
Clinical scenario
STEMI 4 1.181 (1.07–1.29) 0.001
ACS and non-STEMI 2 0.999 (0.60–1.68) 0.997
Type of administration
Intravenous 3 1.489 (1.29–1.71) 0.001
Subcutaneous 2 0.900 (0.70–1.14) 0.396
Follow-up
>6 2 0.900 (0.70–1.14) 0.396
≤6 4 1.224 (1.11–1.34) 0.001
S.G.A. for TVR according to OR
Sample size
>500 3 0.938 (0.64–1.35) 0.733
≤500 3 0.674 (0.17–2.64) 0.571
Clinical scenario
STEMI 3 1.193 (0.71–1.98) 0.499
ACS and non-STEMI 2 0.727 (0.43–1.20) 0.218
Type of administration
Intravenous 3 1.308 (0.62–2.74) 0.477
Subcutaneous 2 0.821 (0.53–1.25) 0.362
Follow-up
>6 4 0.820 (0.54–1.23) 0.341
≤6 2 1.334 (0.61–2.87) 0.463
S.G.A. for stroke according to OR
Sample size
>500 6 0.964 (0.69–1.33) 0.827
≤500 1 0.215 (0.01–4.62) 0.326
Clinical scenario
STEMI 5 0.898 (0.59–1.36) 0.611
ACS and non-STEMI 1 0.940 (0.47–1.85) 0.859
Type of administration
Intravenous 2 0.915 (0.50–1.65) 0.770
Subcutaneous – – –
Follow-up
>6 2 0.971 (0.44–2.10) 0.940
≤6 5 0.935 (0.65–1.33) 0.713
S.G.A. for major bleeding according to OR
Sample size
>500 15 0.868 (0.76–0.99) 0.036
≤500 6 0.499 (0.21–1.16) 0.110
Clinical scenario
STEMI 11 0.860 (0.71–1.03) 0.106
ACS and non-STEMI 6 0.889 (0.71–1.10) 0.284
Type of administration
Intravenous 11 0.720 (0.57–0.89) 0.004
Subcutaneous 3 0.904 (0.54–1.50) 0.699
Follow-up
>6 5 0.579 (0.38–0.87) 0.009
≤6 16 0.894 (0.77–1.02) 0.110
S.G.A. for re-myocardial infarction according to OR
Sample size
>500 13 0.756 (0.67–0.84) 0.001
≤500 5 0.838 (0.49–1.43) 0.518
Clinical scenario
STEMI 9 0.665 (0.54–0.80) 0.001
ACS and non-STEMI 6 0.785 (0.68–0.90) 0.001
Type of administration
Intravenous 10 0.809 (0.71–0.92) 0.001
Subcutaneous 3 0.624 (0.37–1.02) 0.063
Table 3 (Continued )
Subgroup Studies
(n)
Odd ratio
(95% CI)
p-Value
Follow-up
>6 4 0.837 (0.52–1.33) 0.456
≤6 14 0.755 (0.67–0.84) 0.001
S.G.A. for mortality according to OR
Sample size
>500 14 0.661 (0.58–0.74) 0.001
≤500 3 0.551 (0.14–2.06) 0.376
Clinical scenario
STEMI 11 0.659 (0.56–0.76) 0.001
ACS and non-STEMI 4 0.934 (0.72–1.20) 0.600
Type of administration
Intravenous 7 0.705 (0.55–0.89) 0.004
Subcutaneous 3 0.598 (0.45–0.79) 0.001
Follow-up
>6 5 0.445 (0.33–0.55) 0.001
≤6 12 0.767 (0.66–0.88) 0.001
S.G.A. for thrombosis according to OR
Sample size
>500 2 0.737 (0.62–0.87) 0.001
≤500 4 1.289 (0.56–2.92) 0.544
Clinical scenario
STEMI 5 0.754 (0.63–0.88) 0.001
ACS and non-STEMI – – –
Type of administration
Intravenous 5 0.754 (0.63–0.88) 0.001
Subcutaneous – – –
Follow-up
>6 2 1.778 (0.23–13.58) 0.579
≤6 4 0.750 (0.63–0.88) 0.001
S.G.A. for major adverse cardiovascular events according to OR
Sample size
>500 13 0.765 (0.71–0.82) 0.001
≤500 5 0.788 (0.48–1.29) 0.348
Clinical scenario
STEMI 11 0.714 (0.65–0.78) 0.001
ACS and non-STEMI 5 0.851 (0.75–0.95) 0.007
Type of administration
Intravenous 9 0.804 (0.72–0.89) 0.001
Subcutaneous 3 0.886 (0.74–1.04) 0.156
Follow-up
>6 4 0.875 (0.73–1.04) 0.138
≤6 14 0.745 (0.68–0.80) 0.001
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 2 1 3 – 2 2 4218tests showed that there were no potential publication bias
among the included RCTs (Begg test, p = 0.235; Egger test,
p = 0.235).
4.6. Incidence of stent thrombosis
A total 5025 patients were included from 9 RCTs that provided
data on thrombosis. Overall incidence of thrombosis was
14.88%; 13.48% in LMWH group and 16.24% in UFH group. In
fact, 3 out of 9 comparisons did not present any thrombosis
events in 2 comparative arms; therefore, the remaining 6 RCTs
(4333 patients) were used to perform the meta-analysis. Pooled
analysis indicated that LMWH compared to UFH signiﬁcantly
decreased the incidence of thrombosis with an OR of 0.754
(95% CI: 0.63–0.89; p = 0.4) using the ﬁxed effects model.
No signiﬁcant heterogeneity was observed among the RCTs
(chi-squared = 7.52, I2 = 0.0%, p = 0.6). Begg and Egger tests
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i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 2 1 3 – 2 2 4220showed that there were no potential publication bias among
the included RCTs (Begg test, p = 0.297; Egger test, p = 0.297).
4.7. MACE
A total of 39,490 patients were included from 18 RCTs reporting
on the incidence of MACE. Overall incidence of MACE was
10.65%; 9.05% in LMWH and 11.7% in UFH group (Table 2).
Pooled analysis indicated that UFH compared to LMWH
signiﬁcantly increased the incidence of MACE with an OR of
0.766 (95% CI: 0.71–0.82; p < 0.001) using the random effects
model. Signiﬁcant heterogeneity was observed among the
RCTs (chi-squared = 29.76, I2 = 42.9%, p = 0.02). A subgroup
analysis is presented in Table 3.
4.8. Mortality
Twenty-three RCTs (43,912 patients) reported on death.
Mortality occurred in 2.43% (452 patients) in LMWH group
and 5% (1271 patients) in UFH group. In fact, 6 out of 23
comparisons did not present any postoperative death events
in 2 comparative arms; therefore, the remaining 17 RCTs
(41,883 cases) were used to perform the meta-analysis.
Pooled treatment effect analysis revealed that LMWHsigniﬁcantly decreased mortality with an OR of 0.66 (95%
CI: 0.58–0.74; p < 0.001) using the random effects model
(Fig. 6). Signiﬁcant heterogeneity was observed among the
RCTs (chi-squared = 40.6, I2 = 60.6%, p = 0.001). A subgroup
analysis is presented in Table 3. Pooled treatment effect
analysis revealed that LMWH compared to UFH therapy
signiﬁcantly decreased mortality in patients with STEMI (OR
of 0.65; 95% CI: 0.56–0.76; p = 0.001) compared to ACS and non-
STEMI (OR of 0.93; 95% CI: 0.72–1.20; p = 0.6). Intravenous
administration (OR of 0.70; 95% CI: 0.55–0.89; p = 0.004) and
subcutaneous administration (OR of 0.59; 95% CI: 0.45–0.79;
p = 0.001) had statistically similar effects in terms of mortality.
5. Discussion
UFH during PCI is a mainstay of thrombotic therapy, whereas it
has to be adjusted on the basis of patient's activated clotting
time.4–7 Difﬁculties in achieving reliable levels of anti-
coagulation due to its higher degree of protein binding,
inactivation by platelet factor, tendency toward platelet
activation and the risk of heparin-induced nephropathy cause
limitations of UFH application.8–10 LMWH represents an
alternative anticoagulant that provides more stable and
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Fig. 5 – Forest plot of odds ratio (OR) for treatment with heparin on incidence of major bleeding.
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 2 1 3 – 2 2 4 221predictable anticoagulation with no need to continuous
infusion and anticoagulant monitoring.8–10
It is still unclear as what type of heparin is the most
appropriate, safe and efﬁcient anticoagulant for MI patients
undergoing PCI. Our ﬁndings revealed that using LMWH was
associated with signiﬁcantly better TIMI ﬂow compared to
UFH; therefore, administration of LMWH should be preferred
in order to achieve complete perfusion. Sabatine et al.19 also
previously suggested that in order to improve TIMI ﬂow and
achieve complete perfusion, LMWH should be used, which is
consistent with our ﬁndings. Our subgroup analysis showed
that the incidence of optimal TIMI ﬂow after MI was
signiﬁcantly different between the receivers of LMWH and
UFH in terms of the route of administration (either intravenous
or subcutaneous) and clinical scenario (either ACS, non-STEMI
or STEMI).
TVR was deﬁned as ischemia-driven PCI of target lesions
due to re-stenosis or re-occlusion within the stent or in the
adjacent 5 mm of the distal or proximal segment. The ﬁndings
of our study indicated that the incidence of TVR was similar
between LMWH and UFH groups; thus both heparin types were
associated with comparable TVR. Li et al. claimed thatfollowing administration of enoxaparin, the incidence of
TVR decreased with a tendency toward reduced re-MI.26,27
According to our ﬁndings enoxaparin also signiﬁcantly
decreased the incidence of re-MI. Previous studies proposed
LMWH to be a more potent anticoagulant in terms of
decreasing re-MI compared to UFH. Our analysis of a larger
body of literature and more subjects conﬁrmed this stronger
prophylactic effect of LMWH compared to UFH.
The results of our sensitive analysis showed that in terms
of decreasing re-MI LMWH was superior to UFH for both stable
and unstable patients especially when administered intrave-
nously. Prophylactic effects against re-MI were shown to be
stronger in cases of intravenous compared to subcutaneous
administration; therefore, it can be suggested that for patients
with a history of MI, intravenous administration of LMWH may
be more beneﬁcial than subcutaneous administration or the
administration of UFH with the view to avoiding recurrent
infarction.
Several studies showed that increased efﬁciency of LMWH
may be accompanied by an increased risk of hemorrhage,
especially in high risk patients, such as elderly patients with
history of chronic renal impairment. In cases of renal
Overall  (I-sq uared = 60.6 %,  p = 0. 001)
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Fig. 6 – Forest plot of odds ratio (OR) for treatment with heparin on incidence of mortality.
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 2 1 3 – 2 2 4222impairment there is deﬁnite accumulation of LMWH, whereas
no antagonist to LMWH is available. This accumulation might
subsequently increase the risk of major bleeding episodes.
Thus, the dose of LMWH needs to be adjusted in this fragile
population.38–41 Nevertheless, the results of our study showed
that the risk of hemorrhage was signiﬁcantly lower in LMWH
receivers compared to UFH, particularly when administered
intravenously; it was associated with better therapeutic
response as well as less major bleeding. Puymirat et al.22 also
reported that LMWH signiﬁcantly reduced the risk of major
bleeding, and this complication particularly decreased in cases
of intravenous injections, which is in agreement with our
study. Montalescot et al. stated that subcutaneous adminis-
tration of enoxaparin was more common in stable and occult
coronary syndrome patients; however, intravenous injection
could be well adopted to PCI and emergency conditions
pharmacologically.21 In addition, it provided urgent and
predictable anticoagulation, which is effective for full 2 h.23–24
Our ﬁndings also revealed that intravenous injection was the
most effective route of administration of heparin. This advan-
tage is achieved with a protocol that is simpler than
that typically used for UFH: one intravenous bolus withoutanticoagulation monitoring, the same dose with or without
glycoprotein IIb/IIIa inhibitors, and immediate sheath removal
after femoral or radial PCI.42
Several preoperative risk stratiﬁcation models such as the
additive European System for Cardiac Operative Risk Evalua-
tion (EuroSCORE) and Cardiac Surgery Score (CASUS) are
currently in daily use in cardiac surgery.43,44 These scores are
population-based and offer a probability of occurrence in a
set of patients with similar characteristics. A prediction of
individual outcome especially mortality might be achieved. The
present study, analyzing 43,912 patients, claims that adminis-
tration of LMWH in comparison to UFH, is able to signiﬁcantly
reduce the risk of mortality in patients with MI. Our subgroup
analysis demonstrated that administration of LMWH in STEMI
patients could considerably reduce mortality, however, that did
not have such effect in stable and ACS patients. Also both
intravenous administration and subcutaneous administration
of LMWH were found to be able to decrease mortality. Silvain
et al. reported that LMWH had a remarkable preference to UFH
for decreasing the risk of mortality.45
Patients may develop in-stent-thrombosis following PCI.
This complication is of critical importance due to formation of
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 2 1 3 – 2 2 4 223blood clot and reduction of blood supply to distal vessels, and a
decrease in reperfusion to the myocardium surrounding the
site of thrombosis. Our results indicated that patients under
LMWH therapy may less frequently develop thrombosis and
MACE during PCI compared to UFH.
Finally, we can conclude that the most appropriate type of
heparin for patients with MI undergoing PCI seems to be
LMWH with higher efﬁcacy and lower incidence of complica-
tions compared to UFH. LMWH administration is also more
convenient with no need for continuous infusion or tight
anticoagulation monitoring. Nevertheless, it is imperative that
the outcome after PCI as a procedure in patients receiving
either forms of heparin is dependent on many other factors,
namely gender, comorbidities, time from onset of symptoms
to hospitalization etc.
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